Alkermes plc
Research Alkermes plc (ALKS) on Bullrun: valuation model: 61.4% overvalued, market cap USD 8.24B, P/E 127.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALKS
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal61.4% overvalued
- Market capUSD 8.24B
- P/E127.8
- Financial periodQ1 2026
- RevenueUSD 392.91M
- Net income-USD 66.48M
- Free cash flow-USD 169.83M
- Gross margin84.3%
Valuation Snapshot
Bullrun's latest valuation model marks Alkermes plc as 61.4% overvalued; latest market cap is USD 8.24B; P/E is 127.8.
Peer valuation comparison
Latest P/E is 127.82x versus a Healthcare sector median of 24.46x (422.6% above).
Latest P/E is 127.82x versus a Ireland median of 22.15x (477.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.48B | USD 241.70M | USD 480.33M | 86.7% | 1.43 | USD 388.57M | USD 0 | USD 1.82B |
| FY2024 | USD 1.56B | USD 367.10M | USD 405.64M | 84.2% | 2.17 | USD 291.15M | USD 75.54M | USD 1.46B |
| FY2023 | USD 1.66B | USD 355.80M | USD 353.31M | 84.8% | 2.1 | USD 457.47M | USD 290.73M | USD 1.20B |
| FY2022 | USD 1.11B | -USD 158.30M | -USD 17.21M | 80.4% | -0.97 | USD 292.47M | USD 293.27M | USD 1.04B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.24B | 127.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.63B | 19.6 | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.66B | 13.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.63B | 22.6 | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.29B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.77B | n/a | n/a | n/a |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Alkermes plc overvalued or undervalued?
Bullrun's valuation model currently marks Alkermes plc as 61.4% overvalued.
What is Alkermes plc's market cap?
Alkermes plc's market capitalization is USD 8.24B.
What is Alkermes plc's P/E ratio?
Alkermes plc's price-to-earnings (P/E) ratio is 127.8.
What does Alkermes plc do?
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.